Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile?

Clinical Microbiology-Immunology Laboratories, UNC Hospitals, CB 7600, Chapel Hill, NC 27514, USA.
Journal of clinical microbiology (Impact Factor: 4.16). 05/2008; 46(4):1523-5. DOI: 10.1128/JCM.02100-07
Source: PubMed

ABSTRACT A two-step algorithm for the detection of Clostridium difficile by the use of C. Diff Quik Chek (TechLab, Blacksburg, VA) and a tissue culture cytotoxicity neutralization assay was found to be more sensitive than the widely used solid-phase enzyme immunoassay (EIA), the Premier toxin A and B EIA (Meridian Bioscience, Cincinnati, OH), and a newly developed, rapid single-test EIA for C. difficile toxins A and B (Tox A/B Quik Chek; TechLab).

  • [Show abstract] [Hide abstract]
    ABSTRACT: This guideline will examine the use of molecular tests and multi-test algorithms for the diagnosis of Clostridium difficile Infections (CDI). These new tests, alone or in a multi-step algorithm consisting of more than one assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save money overall by initiating appropriate treatment and infection control protocols sooner and by possibly reducing length of hospital stay [1]. We recommend testing only unformed stool in patients with clinically significant diarrhea (CSD) by a molecular method or by a two to three step algorithm.
    Clinical Infectious Diseases 06/2013; · 9.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nucleic acid amplification techniques (NAATs) represent a major advance in the diagnosis of Clostridium difficile (C. difficile) infection. This review analyzes the different options available for a molecular diagnosis of C. difficile infection, as well as the strengths and weaknesses of NAATs. The performances of seven commercials NAATs are compared (BD GeneOhm Cdiff, Illumigene C. difficile, Xpert C. difficile, BD Max Cdiff, Portrait Toxigenic C. difficile, ProGastro Cd, Seeplex Diarrhea ACE). The sensitivity and the rapidity of NAATs are excellent: additional efforts should focus on the discrimination between infection and colonization. Reporting the DNA load of toxigenic C. difficile in the stool sample may represent a solution. Diagnostic algorithms combining immunoassays and NAATs could also improve the specificity and reduce the global cost of this analysis.
    Expert Review of Molecular Diagnostics 09/2013; 13(7):681-92. · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Portrait Toxigenic Clostridium difficile assay is a rapid, qualitative assay for the detection of the tcdB gene of C. difficile in stool specimens from patients suspected of C. difficile infections, and received 510(k) clearance by the US FDA in March 2012. The Portrait Toxigenic C. difficile assay combines novel blocked-primer-mediated helicase-dependent multiplex amplification (bpHDA) technology and chip-based detection in an automated sample-to-result format. The assay requires minimal sample preparation and results are available within 90 min. In a multicenter evaluation, the Portrait Toxigenic C. difficile assay had a sensitivity of 98.2% and specificity of 92.8% compared with toxigenic culture. A comparative study between the Portrait Toxigenic C. difficile assay and three FDA-cleared molecular assays for the detection of toxigenic C. difficile exhibited a high degree of agreement (93.8-97.5%). The Portrait Toxigenic C. difficile assay provides a simple, cost-effective method with broad applicability to panel-based approaches, potentially simplifying workflow.
    Expert Review of Molecular Diagnostics 11/2013; · 4.09 Impact Factor


Available from